Evoke Pharma Addresses FDA Update on Domperidone Supply and Highlights GIMOTI as the Only Approved Treatment for Gastroparesis
Evoke Pharma highlights GIMOTI's role amid FDA's domperidone supply concerns, emphasizing its benefits for gastroparesis patients.Quiver AI SummaryEvoke Pharma, Inc. announces its commitment to addressing...
Evoke Pharma Receives Patent Allowances Expanding Intellectual Property for GIMOTI® Nasal Spray Treatment for Gastroparesis
Evoke Pharma received patent allowances for GIMOTI nasal spray, enhancing its protection for treating diabetic gastroparesis.Quiver AI SummaryEvoke Pharma, Inc., a specialty pharmaceutical company focusing...
Evoke Pharma Reports Second Quarter 2022 Financial Results
Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11%...
Evoke Pharma to Report Second Quarter Results on August 10, 2022
SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for...